Total artificial heart as a bridge to transplantation.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
Since the first implantation of a total artificial heart (TAH) 50 years ago the devices and technique have evolved to provide reliable support for patients with biventricular failure as a bridge to heart transplant. The purpose of this review is to discuss the history and evolution of devices, current devices, critical aspects of patient selection, tips and pitfalls of implantation, and future directions. The most studied device on the market is the SynCardia TAH, which has been implanted in over 2000 patients worldwide and is the only device that is currently Food and Drug Administration approved as a bridge to transplant. The overall survival in patients supported by the device at 1 year is 42% while those that make it to transplant have a 1 year post transplant survival of 83%. A newer device the Aeson TAH (Carmat, Velizy-Villacoublay, France) was first implanted in France in 2013 and is currently under clinical trial in the United States. Significant progress has been made in both the technology and technique of TAH implantation and these devices remain both a reliable and sometimes only option for patients with severe biventricular heart failure.
Identifiants
pubmed: 35649113
doi: 10.1097/MOT.0000000000000982
pii: 00075200-202206000-00011
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-228Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Coselli JS. Nothing like a good feud to spark competition: first use of the total artificial heart. Artif Organs 2022; 46:8–13.
Liotta D, Taliani T, Giffoniello AH, et al. Artificial heart in the chest: preliminary report. Trans Am Soc Artif Intern Organs 1961; 7:318–322.
Cooley DA, Liotta D, Hallman GL, et al. Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol 1969; 24:723–730.
Nothing like a good feud to spark competition: first use of the total artificial heart, Video 1. Available at: https://www.youtube.com/watch?v=gnU1xogRa18 . [Accessed 2 February 2022]
Khan S, Jehangir W. Evolution of artificial hearts: an overview and history. Cardiol Res 2014; 5:121–125.
Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004; 351:859–867.
Dowling RD, Gray LA Jr, Etoch SW, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg 2004; 127:131–141.
Slepian MJ, Alemu Y, Girdhar G, et al. The SynCardia() total artificial heart: in vivo, in vitro, and computational modeling studies. J Biomech 2013; 46:266–275.
Noly PE, Ben Ali W, Lamarche Y, Carrier M. Status, indications, and use of cardiac replacement therapy in the era of multimodal mechanical approaches to circulatory support: a scoping review. Can J Cardiol 2020; 36:261–269.
Copeland J, Langford S, Giampietro J, et al. Total artificial heart update. Surg Technol Int 2021; 39:243–248.
SynCardia 70cc TAH-t for destination therapy (DT) (RA-540). Published 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT02232659 . [Accessed 9 February 2022]
Carpentier A, Latremouille C, Cholley B, et al. First clinical use of a bioprosthetic total artificial heart: report of two cases. Lancet 2015; 386:1556–1563.
Han JJ. Aeson—the Carmat total artificial heart is approved for enrollment in the United States. Artif Organs 2021; 45:445–446.
Carmat to resume implants of Aeson artificial heart in October. Reuters. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/carmat-resume-implants-aeson-artificial-heart-october-2022-01-31/ . [Accessed 2 October 2022]
Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device – final report. N Engl J Med 2019; 380:1618–1627.
Dandel M, Hetzer R. Temporary assist device support for the right ventricle: preimplant and postimplant challenges. Heart Fail Rev 2018; 23:157–171.
Copeland JG, Copeland H, Gustafson M, et al. Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg 2012; 143:727–734.
Arabia FA, Cantor RS, Koehl DA, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. J Heart Lung Transplant 2018; 37:1304–1312.
Aissaoui N, Morshuis M, Paluszkiewicz L, et al. Comparison of biventricular and left ventricular assist devices for the management of severe right ventricular dysfunction in patients with end-stage heart failure. ASAIO J 2014; 60:400–406.
Loforte A, Stepanenko A, Potapov EV, et al. Temporary right ventricular mechanical support in high-risk left ventricular assist device recipients versus permanent biventricular or total artificial heart support. Artif Organs 2013; 37:523–530.
Cheng A, Trivedi JR, Van Berkel VH, et al. Comparison of total artificial heart and biventricular assist device support as bridge-to-transplantation. J Card Surg 2016; 31:648–653.